ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals (OTCBB:RXHN) announced a signed agreement between the Company and the National Institute of Neurological Disorders and Stroke (NINDS), a division of the National Institutes of Health. According to the agreement, Rexahn’s lead CNS compound, RX-10100, will be submitted for pharmacological evaluation to NINDS’ Anticonvulsant Screening Program (ASP), a public/private partnership with academic and industry effort focused on discovery, optimization and development of drugs for epilepsy and other serious conditions.
